EICHORCondition: Melanoma (Skin) · Sponsor: ECOG-ACRIN Cancer Research Group
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UAB Comprehensive Cancer Center | Birmingham, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Arizona Cancer Center at University of Arizona Health Sciences Center | Tucson, Arizona, United States | — |
| Hembree Mercy Cancer Center at St. Edward Mercy Medical Center | Fort Smith, Arkansas, United States | — |
| Arkansas Cancer Research Center at University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| Kaiser Permanente - Deer Valley | Antioch, California, United States | — |
| Alta Bates Summit Comprehensive Cancer Center | Berkeley, California, United States | — |
| Peninsula Medical Center | Burlingame, California, United States | — |
| Southern California Permanente Medical Group | Downey, California, United States | — |
| Kaiser Permanente - Fremont | Fremont, California, United States | — |
| Marin Cancer Institute at Marin General Hospital | Greenbrae, California, United States | — |
| Kaiser Permanente Medical Center - Hayward | Hayward, California, United States | — |
+ 521 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00003641